To require a report on foreign investment in the pharmaceutical industry of the United States.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require a report on foreign investment in the pharmaceutical industry of the United States., changes federal law or congressional policy affecting importers, exporters, and commercial firms. The main policy domain is Trade, Healthcare, Finance.
Who Benefits and How
importers, exporters, and commercial firms may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, importers, exporters, and commercial firms may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section id49b7723662af4169b8b41578cc20f845: 1. Short title This Act may be cited as the United States Pharmaceutical Supply Chain Review Act.
- Section id8E1BFE9D5FAC4D068C751624A028FD4B: 2. Report on foreign investment in pharmaceutical industry Not later than 1 year after the date of the enactment of this Act, and annually thereafter, the...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require a report on foreign investment in the pharmaceutical industry of the United States., changes federal law or congressional policy affecting importers, exporters, and commercial firms.
Key Policy Areas
Trade, Healthcare, Finance
Primary Purpose
This bill, To require a report on foreign investment in the pharmaceutical industry of the United States., changes federal law or congressional policy affecting importers, exporters, and commercial firms.
Policy Domains
Whole bill
Identified Gains
- importers, exporters, and commercial firms
Identified Costs
- federal implementing agencies
- importers, exporters, and commercial firms
Sponsors
Legislative Progress
IntroducedMs. Warren (for herself and Mr. Rubio) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_commission"
- → The commission identified in the operative section
- "secretary_of_commerce"
- → Secretary of Commerce
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology